04327nam 22010813a 450 991036775390332120250203235428.09783039215874303921587610.3390/books978-3-03921-587-4(CKB)4100000010106178(oapen)https://directory.doabooks.org/handle/20.500.12854/40955(ScCtBLL)b9b0c415-7ac0-4b5d-96e8-4bd324100c62(OCoLC)1163812676(oapen)doab40955(EXLCZ)99410000001010617820250203i20192019 uu engurmn|---annantxtrdacontentcrdamediacrrdacarrierAnticancer DrugsNiamh M. O'Boyle, Mary J. MeeganMDPI - Multidisciplinary Digital Publishing Institute2019Basel, Switzerland :MDPI,2019.1 electronic resource (214 p.)9783039215867 3039215868 The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody-drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.Chemistrybicsscgraphene oxideindoleandrogenscyclooxygenase-2cyclooxygenase-1heteropolysaccharidedrug conjugationdrug deliveryellipticinechemical linkeroesophageal cancerantiproliferative activitytopoisomerase II?-lactamDSDantibodytopoisomerase inhibitorsmagnetic targetingcisplatin resistancesteroidogenesis[18F]FDG PET/CTheterocyclic chemistrydehydroepiandrosteroneantimitotic3-vinylazetidin-2-onesglioblastomaand cancer therapyintestinal mucositisCombretastatin A-4metabolismanti-cancer drugsmaghemiteCOX-1 inhibitoranticancerCYP17A1conjugate and hybrid drugsinflammationsnticancer drugsP450c17tumorigenesiscisplatinbiomarker profilingcancer drug designtubulincytochrome P4505-fluorouracilprostate cancerabirateroneNCI screenradiationcancer immunotherapymicrotubule targeted drugscancertreatment resistanceChemistryO'Boyle Niamh M1296346Meegan Mary JScCtBLLScCtBLLBOOK9910367753903321Anticancer Drugs3024025UNINA